Embodiment
The compounds of this invention can be accomplished according to following method and step.
At first; The starting compound (referring to embodiment 1) for preparing formula (II) with reference to the method for patent GB2098602A or other document introduction; This starting compound contains chiral centre; Those skilled in the art can split it through known method, for example, and through forming separable non-mapping salt or complex crystal; Formation can be carried out isolating non-enantiomer derivative through for example crystallization, gas liquid chromatography or liquid chromatography; A kind of enantiomorph and enantiomorph specific reagent are carried out selective reaction, for example oxydasis or reduction, the enantiomorph of separation modification and unmodified then; Perhaps in chiral environment, for example in chiral environment, for example chiral support (for example having the silica gel that combines chiral ligand) goes up or in the presence of chiral solvent, carries out gas liquid chromatography or liquid chromatography.Be appreciated that when required enantiomorph changes into another kind of chemical entities through one of above-mentioned separation method, also need to discharge in addition the step of required enantiomeric form.
R shown in the formula (II) in the starting compound
1Be H or C
1-4Alkyl; X independently is H, halogen, CF
3, C
1-3Alkyl, alkoxyl group, alkylthio or phenyl.
After the optical isomer of starting compound was ready to shown in the formula (II), those skilled in the art can adopt following two schemes to prepare compound shown in the formula of the present invention (I).
Scheme one:
In this programme, the R shown in the formula (III) in the starting compound
3For being H, formyl radical, ethanoyl, halo ethanoyl, benzoyl-, carbobenzoxy-(Cbz) (Cbz), tertbutyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc); R
2For methyl, sec.-propyl, isobutyl-, sec.-butyl, benzyl, methylthio ethyl, methylol, or be R
4(CH
2)
n-(during n=1, R
4Be hydroxyl, sulfydryl, carboxylic acid group, carboxamido-group, imidazolyl, p-hydroxybenzene, indyl; During n=2, R
4Be first sulphur, carboxylic acid group, carboxamido-group; During n=3, R
4Be urea groups; During n=4, R
4Be amido), or be R
5R
6(CH)-(R
5Be methyl, R
6Be hydroxyl).
The a certain optical isomer of starting compound shown in starting compound shown in the above-mentioned formula (III) and the formula (II), enantiomorph, diastereomer, raceme mixture generate the optical isomer of compound shown in the formula of the present invention (I) through condensation reaction.
Scheme two:
All the other are all identical with scheme one, just R
3With R
2With-HN-form 3-7 unit ring (this ring can be saturated also can be undersaturated, also maybe be by one or more halogen, hydroxyl, C
1-4Alkyl, C
1-4Alkoxyl group replaces), R
2With R
3With-HN-formation 3-7 unit ring.R
3With R
2To form compound concrete structure shown in the formula (I) of ring following with-HN-:
This moment n=0-4, R
7Be one or more halogen, hydroxyl, C
1-4Alkyl, C
1-4Alkoxyl group.
Like above-mentioned two schemes, relate to a step condensation reaction shown in the formula of the present invention (I) in the preparation of compound, those skilled in the art can utilize condensing agent to carry out the preparation of this compound through known method.For example utilize DCC, DIC, BDP, BOP, EDC, AOP, PyAOP, PPAA, TOTU, HATU, HAPyU, HAMDU, HBTU, HBTyU, HBMDU, HBPyU, DEPBT, HOAT, HOBT, PyBOP, TATU, TBTU, PyBrop, PyCloP, CIP, TFFH, BTFFH, PyCIU, CDTP, BOP-C1, DPPA, DEPC, BOMI, BDMP to wait and realize this condensation reaction.
The concrete embodiment that below comprises explains the present invention with the preparation of several groups of compounds, does not constitute the restriction to the disclosure of invention.Agents useful for same and midbody perhaps can be provided by commerce in the instance, perhaps can easily be prepared according to the normative document method by those skilled personnel of organic synthesis field.Those persons skilled in the art of this area can know to also have other to prepare the method for The compounds of this invention.
Starting compound
The preparation of embodiment 1:1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and optical isomer thereof
1, the preparation of racemic 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine
The method of reference literature (Chinese Journal of Pharmaceuticals, 2001; 32 (8): 337-9), through p-chlorobenzyl cyanide and 1, the 3-dibromopropane annulation of going ahead of the rest, preparation cyclobutyl midbody prepares through Grignard reaction and reduction reaction again.Yield 56.2%.
2, split instance: racemic 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine 20.3g that step 1 is prepared is with the mixed solution 300ml dissolving of acetone/methyl alcohol=1: 0.13: 0.7 (volume ratio), adds L (+)-tartrate 12.1g backflow then 0.5 hour, naturally cooling; Room temperature left standstill 2-4 days; There is crystallization to generate, filters, wash with cold acetone (100ml/13ml); After drying, get sample 10.3g, yield 33%.
Get above-mentioned crystallized product 25g, add acetonitrile/water/ethanol 300ml/65ml/30ml and refluxed 1 hour, be cooled to room temperature and cross and filter white crystals product 18g, yield 72%.After alkaline purification, get free alkali.Optical purity 99.7%.This product is (S)-1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine.
With the above, mother liquor is obtained another kind of optically active isomer, yield 75.2% with D-(-)-tartrate fractionation.After alkaline purification, get free alkali.Optical purity 99.4% is (R)-1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine.
(chiral column is ULTRON ES-OVM (150mmx4.6mm), and moving phase is 0.01MKH with chiral column
2PO
4/ CH
3OH (70: 30), ultraviolet detection wavelength are 200nm) measure the chiral purity of optical isomer, the result shows that the optical purity of these compounds is all greater than 99.0%.
First group
Embodiment 2:2-(Boc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } preparation of ethanamide and isomer thereof
Get dissolving with the anhydrous THF of 3ml of obtaining among the embodiment 1 without 1-[1-(4-chloro-phenyl-) the cyclobutyl]-3-methylbutylamine 250mg that splits and 210mg N-(tertbutyloxycarbonyl)-2-Padil.And then take by weighing 220mg DCC, with the anhydrous THF dissolving of 25ml.The THF drips of solution of DCC is added in the reaction soln.Dropwise back stirring at room reaction and spend the night, have a large amount of white precipitates to generate.Filtering precipitate, and should precipitate more than 3 times with the anhydrous diethyl ether repetitive scrubbing.Collect filtrating and the used ether of washing precipitation, revolve after doing thick product, obtain 2-(Boc protects amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl with the column chromatography method separation and purification then } ethanamide.
Adopt 1-[1-(4-chloro-phenyl-) the cyclobutyl]-3-methylbutylamine split to carry out above-mentioned same reaction and treating processes, can obtain 2-(Boc protects amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl two kinds of optical isomers of ethanamide.
Embodiment 3:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } preparation of ethanamide and isomer thereof
With embodiment 2 products therefrom 2-(Boc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } ethanamide or its optical isomer join CF
3Dissolve among the COOH.This solution is stirring reaction Ex-all CF after hour at room temperature
3COOH, the muddy shape thing of adularescent generates.It is dissolved in the anhydrous diethyl ether, and with the saturated sodium bicarbonate solution repetitive scrubbing till the liquid that washes out becomes neutrality.Wash this diethyl ether solution 2-3 time with saturated sodium-chloride water solution then, and use anhydrous sodium sulfate drying.The filtering siccative removes solvent under reduced pressure, and the gained bullion obtains 2-(amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl with the column chromatography method separation and purification then } ethanamide or its optical isomer.
Embodiment 4:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } preparation of acetamide hydrochloride:
With embodiment 3 products therefrom 2-(amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } ethanamide with the dissolving of a little anhydrous diethyl ether after; Add the salt acid ether; Should have a large amount of white precipitate crystallizations to produce, this crystallization is 2-(amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } acetamide hydrochloride.
Second group
Embodiment 5:2-(Boc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } preparation of propionic acid amide and isomer thereof
Pressing embodiment 2 methods will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and N-(tertbutyloxycarbonyl)-2-amino-this compound of propionic acid prepared in reaction that splits or split, thereby obtains product.
Embodiment 6:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } preparation of propionic acid amide and isomer thereof
Press embodiment 3 methods, with gained compound among the embodiment 5 at CF
3Protection base among the COOH on the deaminize, thus product obtained.
Embodiment 7:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } preparation of propionamide hydrochloride
Press this salt of embodiment 4 methods preparation, thereby obtain product.
The 3rd group
Embodiment 8:2-(Boc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-methylbutyryl amine
Pressing embodiment 2 will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and N-(tertbutyloxycarbonyl)-2-amino-this compound of 3 Methylbutanoic acid prepared in reaction that splits or split, thereby obtains product.
Embodiment 9:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-methylbutyryl amine
Press embodiment 3 methods, with embodiment 8 gained compounds at CF
3Protection base among the COOH on the deaminize, thus product obtained.Molecular weight is 348.91 (C
20H
29ClN
2O); MS (ESI): 350 (M+H
+).
Embodiment 10:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-methylbutyryl amine hydrochlorate
Press this salt of embodiment 4 methods preparation, thereby obtain product.
The 4th group
Embodiment 11:2-(Boc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 4-methylpent acid amides
Pressing embodiment 2 methods will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and N-(tertbutyloxycarbonyl)-2-amino-this compound of 4-methylvaleric acid prepared in reaction that splits or split, thereby obtains product.
Embodiment 12:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 4-methylpent acid amides
Press embodiment 3 methods, with embodiment 11 gained compounds at CF
3Protection base among the COOH on the deaminize, thus product obtained.
Embodiment 13:2-(Boc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-methylpent acid amides
Pressing embodiment 2 methods will react without 1-[1-(4-chloro-phenyl-) the cyclobutyl]-3-methylbutylamine that splits or split and N-(tertbutyloxycarbonyl)-2-amino-3 methylvaleric acid, thereby obtain product.
Embodiment 14:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-methylpent acid amides
Press embodiment 3 methods, with embodiment 13 gained compounds at CF
3Protection base among the COOH on the deaminize, thus product obtained.
The 5th group
Embodiment 15:2-(Boc protect amino) N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-Phenylpropionamide
Pressing embodiment 2 methods will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and N-(tertbutyloxycarbonyl)-2-amino-this compound of 3-phenylpropionic acid prepared in reaction that splits or split, thereby obtains product.
Embodiment 16:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-Phenylpropionamide
Press embodiment 3 methods, with embodiment 15 gained compounds at CF
3Protection base among the COOH on the deaminize, thus product obtained.
The 6th group
Embodiment 17:2-(Boc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-methylthio group yulocrotine
Pressing embodiment 2 methods will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and N-(tertbutyloxycarbonyl)-2-amino-this compound of 4-methylmercapto butyric acid prepared in reaction that splits or split, thereby obtains product.
Embodiment 18:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-methylthio group yulocrotine
Press embodiment 3 methods, with embodiment 17 gained compounds at CF
3Protection base among the COOH on the deaminize, thus product obtained.
The 7th group
Embodiment 19:2-(Boc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-hydroxyl propionic acid amide
Pressing embodiment 2 methods will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and N-(tertbutyloxycarbonyl)-2-amino-this compound of 3-hydroxy-propionic acid prepared in reaction that splits or split, thereby obtains product.
Embodiment 20:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-hydroxyl propionic acid amide
Press embodiment 3 methods, with embodiment 19 gained compounds at CF
3Protection base among the COOH on the deaminize, thus product obtained.
The 8th group
Embodiment 21:2-(Boc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-maloyl group amine
Pressing embodiment 2 methods will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and N-(tertbutyloxycarbonyl)-this compound of 2 amino 3 hydroxybutyric acid prepared in reaction that splits or split, thereby obtains product.
Embodiment 22:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-maloyl group amine
Press embodiment 3 methods, with embodiment 21 gained compounds at CF
3Protection base among the COOH on the deaminize, thus product obtained.
The 9th group
Embodiment 23:2-(Fmoc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-sulfydryl propionic acid amide
Get without 1-[1-(4-chloro-phenyl-) the cyclobutyl]-3-methylbutylamine 250mg that splits or split and 410mg N-(9-fluorenylmethyloxycarbonyl)-2-amino-3-mercaptopropionic acid and dissolve, to wherein adding the 0.5ml triethylamine with the 5ml dry DMF.And then take by weighing 300mg BDP, dissolve with the 25ml dry DMF.The DMF drips of solution of BDP is added in the reaction soln.Dropwise the back stirring at room and react half hour, have a large amount of white precipitates to generate.Filtering precipitate, and should precipitate more than 3 times with the anhydrous diethyl ether repetitive scrubbing.Collect filtrating and the used ether of washing precipitation, revolve after doing thick product, obtain 2-(Fmoc protects amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl with the column chromatography method separation and purification then }-3-sulfydryl propionic acid amide.
Embodiment 24:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-sulfydryl propionic acid amide
With embodiment 23 products therefrom 2-(Fmoc protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-3-sulfydryl propionic acid amide joins 0.05-0.1mol/L (n-Bu)
4N
+F
-DMF in dissolve.This solution is stirring reaction Ex-all DMF after half hour at room temperature, and the muddy shape thing of adularescent generates.It is dissolved in the anhydrous diethyl ether, and with the saturated sodium bicarbonate solution repetitive scrubbing till the liquid that washes out becomes neutrality.Wash this diethyl ether solution 2-3 time with saturated sodium-chloride water solution then, and use anhydrous sodium sulfate drying.The filtering siccative removes solvent under reduced pressure, and the gained bullion obtains 2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl with the column chromatography method separation and purification then }-3-sulfydryl propionic acid amide.
The tenth group
Embodiment 25:3-(Fmoc protects amino)-4-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine }-the butyro-preparation of 4-carbonyl
Pressing embodiment 23 methods will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and N-(9-fluorenylmethyloxycarbonyl)-this compound of 2-amino-succinic acid prepared in reaction that splits or split, thereby obtains this product.
Embodiment 26:3-amino-4-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine }-the butyro-preparation of 4-carbonyl
Press embodiment 24 methods, with embodiment 23 gained compounds at 0.05-0.1mol/L (n-Bu)
4N
+F
-DMF in protection base on the deaminize, thereby obtain product.
The 11 group
Embodiment 27:2-(Fmoc protects amino)-N
1The preparation of-{ 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } succinic diamide
Pressing embodiment 23 methods will be without 1-[1-(4-chloro-phenyl-) the cyclobutyl]-3-methylbutylamine that splits or split and N-(9-fluorenylmethyloxycarbonyl)-this compound of 2-amino 4-carboxamido-group propionic acid prepared in reaction, thereby obtains this product.
Embodiment 28:2-amino-N
1The preparation of-{ 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } succinic diamide
Press embodiment 24 methods, with embodiment 27 gained compounds at 0.05-0.1mol/L (n-Bu)
4N
+F
-DMF in protection base on the deaminize, thereby obtain product.
The 12 group
Embodiment 29:4-(Fmoc protect amino)-5-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine }-preparation of 5-carbonyl valeric acid
Pressing embodiment 23 methods will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and N-(9-fluorenylmethyloxycarbonyl)-this compound of 2 aminopentanedioic acid prepared in reaction that splits or split, thereby obtains this product.
Embodiment 30:4-amino-5-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine }-preparation of 5-carbonyl valeric acid
Press embodiment 24 methods, with embodiment 29 gained compounds at 0.05-0.1mol/L (n-Bu)
4N
+F
-DMF in protection base on the deaminize, thereby obtain product.
The 13 group
Embodiment 31:2-(Fmoc protects amino)-N
1The preparation of-{ 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } glutaramide
Pressing embodiment 23 methods will be without 1-[1-(4-chloro-phenyl-) the cyclobutyl]-3-methylbutylamine that splits or split and N-(9-fluorenylmethyloxycarbonyl)-this compound of 2-amino 4-carboxamido-group butyric acid prepared in reaction, thereby obtains this product.
Embodiment 32:2-amino-N
1The preparation of-{ 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } glutaramide
Press embodiment 24 methods, with embodiment 31 gained compounds at 0.05-0.1mol/L (n-Bu)
4N
+F
-DMF in protection base on the deaminize, thereby obtain product.
The 14 group
Embodiment 33:1-{4-(Fmoc protect amino)-5-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine }-5-carbonyl amyl group } preparation of urea
Pressing embodiment 23 methods will be without 1-[1-(4-chloro-phenyl-) the cyclobutyl]-3-methylbutylamine that splits or split and N-(9-fluorenylmethyloxycarbonyl)-this compound of 2-amino 5-diazanyl valeric acid prepared in reaction, thereby obtains this product.
Embodiment 34:1-{4-amino-5-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine }-5-carbonyl amyl group } preparation of urea
Press embodiment 24 methods, with embodiment 33 gained compounds at 0.05-0.1mol/L (n-Bu)
4N
+F
-DMF in protection base on the deaminize, thereby obtain product.
The 15 group
Embodiment 35:2-(Cbz protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-(1H-4-imidazoles) propionic acid amide
Get without 1-[1-(4-chloro-phenyl-) the cyclobutyl]-3-methylbutylamine 250mg that splits or split and 410mg N-(carbobenzoxy-(Cbz))-2-amino-3-(1H-4-imidazoles) propionic acid and dissolve, to wherein adding the 0.5ml triethylamine with the 5ml dry DMF.And then take by weighing 400mg BOP, dissolve with the 25ml dry DMF.The DMF drips of solution of BDP is added in the reaction soln.Dropwise back stirring at room reaction half, have a large amount of white precipitates to generate.Filtering precipitate, and should precipitate more than 3 times with the anhydrous diethyl ether repetitive scrubbing.Collect filtrating and the used ether of washing precipitation, revolve after doing thick product, obtain 2-(Cbz protects amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl with the column chromatography method separation and purification then }-3-(1H-4-imidazoles) propionic acid amide.
Embodiment 36:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-(1H-4-imidazoles) propionic acid amide
With embodiment 35 products therefrom 2-(Cbz protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-3-(1H-4-imidazoles) propionic acid amide joins in the ethanol and dissolves.Then to wherein adding an amount of 10%Pd-C.Hydrogenation is to not inhaling till the hydrogen under the normal temperature and pressure.Leach catalyzer, revolve except that ethanol, the muddy shape thing of adularescent generates.It is dissolved in the anhydrous diethyl ether, washs this diethyl ether solution 2-3 time with saturated sodium-chloride water solution then, and use anhydrous sodium sulfate drying.The filtering siccative removes solvent under reduced pressure, and the gained bullion obtains 2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl with the column chromatography method separation and purification then }-3-(1H-4-imidazoles) propionic acid amide.
The 16 group
Embodiment 37:2-(Cbz protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-(4-hydroxy phenyl) propionic acid amide
Pressing embodiment 35 methods will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and this compound of N-(carbobenzoxy-(Cbz))-2-amino-3-(4-hydroxy phenyl) propionic acid prepared in reaction of splitting or splitting, thereby obtains this product.
Embodiment 38:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-(4-hydroxy phenyl) propionic acid amide
Press embodiment 36 methods, with embodiment 37 gained compounds in ethanolic soln with the protection base on 10% the Pd-C deaminize, thereby obtain product.
The 17 group
Embodiment 39:2-(Cbz protect amino)-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-(1H-indyl) propionic acid amide
Pressing embodiment 35 methods will be without 1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutylamine and this compound of N-(carbobenzoxy-(Cbz))-2-amino-3-(1H-indyl) propionic acid amide prepared in reaction of splitting or splitting, thereby obtains this product.
Embodiment 40:2-amino-N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-preparation of 3-(1H-indyl) propionic acid amide
Press embodiment 36 methods, with embodiment 39 gained compounds in ethanolic soln with the protection base on 10% the Pd-C deaminize, thereby obtain product.
The 18 group
Embodiment 41:N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl } preparation of pyrroles-2-acid amides
Pressing embodiment 2 methods will prepare this compound without 1-[1-(4-chloro-phenyl-) the cyclobutyl]-3-methylbutylamine that splits or split and pyrroles-2-carboxylic acid reaction, thereby obtain product.
Embodiment 42:N-{1-[1-(4-chloro-phenyl-) cyclobutyl]-3-methylbutyl }-4-hydroxyl pyrroles-2-acid amides
Pressing embodiment 2 methods will prepare this compound without 1-[1-(4-chloro-phenyl-) the cyclobutyl]-3-methylbutylamine that splits or split and 4-hydroxyl pyrroles-2-carboxylic acid reaction, thereby obtain product.
Above embodiment product is carried out the ESI mass spectroscopy, enumerate compound all shows expection in the ESI mass spectrum molecular ion peak above the result.Relevant information is referring to table 1:
Table 1 embodiment 2~42 dependency structures and ESI mass spectrum information
More than with specific embodiment the preparation of formula of the present invention (I) compound and enantiomer compound thereof has been described.The compound that the present invention is contained is not limited to the content that embodiment enumerates, and comprises that also compound or its enantiomer compound are at pharmacy acceptable salt.
Pharmacy acceptable salt is particularly suitable for medical applications, because compare with initial or basic compound, their solubleness in water is bigger.There is basic nitrogen in The compounds of this invention; Therefore can prepare salify through sour addition with pharmaceutically acceptable mineral acid and organic acid; Mineral acid is hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, phosphoric acid, metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid for example, organic acid for example carbonic acid, acetate, oxalic acid, Phenylsulfonic acid, tosic acid, to bromo-benzene sulfonic acid, Succinic Acid, phenylformic acid, Citric Acid, ethyl sulfonic acid, fumaric acid, glyconic acid, oxyacetic acid, isethionic acid, lactic acid, lactobionic acid, toxilic acid, oxysuccinic acid, methylsulfonic acid, succsinic acid, tosic acid, tartrate and trifluoroacetic acid, amino acid etc.Therefore; This type pharmacy acceptable salt comprises vitriol, pyrosulphate, hydrosulfate, sulphite, hydrosulphite, phosphoric acid salt, monohydric phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate salt, muriate, bromide, iodide, acetate, propionic salt, octylate, acrylate, formate, isobutyrate, more hydrochlorate, caprate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, PHENRAMINE MALEATE, 2-butyne-1; 4-diacid salt, 3-cyclohexyne-2,5-diacid salt, benzoate, chloro-benzoate, phenylacetate, phenpropionate, benzenebutanoic acid salt, Citrate trianion, lactic acid salt, hippurate, beta-hydroxy-butanoic acid salt, glycollate, PHENRAMINE MALEATE, tartrate, mesylate, propanesulfonic acid salt, naphthalene-1-sulphonate, naphthalene-2-sulfonic acid salt, mandelate, glutaminate, arginic acid salt, lysine salt etc.With regard to medical purpose, especially preferably use hydrochloride, provided by the salifiable method of compound among the embodiment 4,7,10, this method is suitable equally for the compound among other embodiment.
On the other hand, can also there be various polymorphics in The compounds of this invention, for example amorphous forms and crystal type.All crystal formations of The compounds of this invention all comprise within the scope of the invention.
In application facet, The compounds of this invention, its optical isomer, pharmaceutical salts, crystalline structure all can be used as the preparation that active constituents of medicine is used for slimming medicine.Below through its pharmacy effect of description of test.
The active toxicity test of slimming medicine
One, method
1. the foundation of fat animal model
Will be just from newborn SD rat except that the blank group, give abundant nutrient fodder and feed, let rat ad libitum access every day, to such an extent as to set up fat animal model rapidly.
2. experiment is divided into groups, dosage is definite and dosage regimen
To just be divided into 21 groups at random from 210 of newborn SD rats, 10 every group, male and female half and half provide abundant nutrient fodder, and each organizes rat ad libitum access every day, and grouping and dosage are following:
(1) blank group: give basal feed and feed.
(2) model group: give nutrient fodder and feed, quantity-unlimiting.
More than two groups all irritate stomach with 1% CMC 99.5 excipient, all the other are respectively tested drug group and all give with nutrient fodder and feed, and are made into corresponding drug level with 1% CMC 99.5 and irritate clothes, the administration volume is 1ml/100g, once a day, continuous irrigation was obeyed 30 days.Dosage design is according to clinical dosage 10mg/ people/sky of positive control medicine sibutramine, according to the dose,equivalent conversion of people and rat and get.
1) the heavy dose of 0.11mg/ml of embodiment 16 compound medicines
2) the low dose of 0.055mg/ml of embodiment 16 compound medicines
3) the heavy dose of 0.11mg/ml of embodiment 22 compound medicines
4) the low dose of 0.055mg/ml of embodiment 22 compound medicines
5) the heavy dose of 0.11mg/ml of embodiment 12 compound medicines
6) the low dose of 0.055mg/ml of embodiment 12 compound medicines
7) the heavy dose of 0.11mg/ml of embodiment 26 compound medicines
8) the low dose of 0.055mg/ml of embodiment 26 compound medicines
9) the heavy dose of 0.11mg/ml of embodiment 14 compound medicines
10) the low dose of 0.055mg/ml of embodiment 14 compound medicines
11) the heavy dose of 0.11mg/ml of embodiment 2 compound medicines
12) the low dose of 0.055mg/ml of embodiment 2 compound medicines
13) the heavy dose of 0.11mg/ml of embodiment 40 compound medicines
14) the low dose of 0.055mg/ml of embodiment 40 compound medicines
15) the heavy dose of 0.11mg/ml of embodiment 41 compound medicines
16) the low dose of 0.055mg/ml of embodiment 41 compound medicines
17) the heavy dose of 0.11mg/ml of embodiment 9 compound medicines
18) the low dose of 0.055mg/ml of embodiment 9 compound medicines
19) sibutramine 0.11mg/ml
3. observation index
1. weigh every day,, and observe stool and urine and general signs then by the body weight administration.
2. respectively organize rat fasting 12h before putting to death, it is long and calculate Li Shi (Lee) index under etherization to survey body long (from nose to anus) and tail.Put to death animal then.
(Lee) family name's index={ body weight (g) * 103}1/3 ÷ body long (cm)
3. get hematometry blood total cholesterol, triglyceride level, total protein, blood sugar;
Get around the sexual organ fat and weigh, fixing subsequent use with 2.5% formaldehyde ethanol, adipocyte number and size under 400 power microscopes in the full visual field of calculating;
5. core, liver, kidney, sexual organ, and fixing subsequent use with 10% formaldehyde solution, observe and have or not pathological change.
4. statistical treatment is respectively organized equal number average and is represented with x ± S, and does the t check and handle.
Two, The selection result
(1) each medication group is to the influence of obese rat total serum protein, triglyceride level, SUV, blood sugar
The result is as shown in table 2, and each medication group total serum protein, blood sugar are compared no obvious statistical significance with model group, blank group; Serum cholesterol, each medication group of triglyceride level are compared variant or significant difference with model group.Explain that respectively testing medicine does not have obvious influence to obese rat total serum protein, blood sugar, each tests the concentration that medicine can obviously reduce endomorphy type rat serum inventory SUV, triglyceride level, with sibutramine similar effect is arranged.
In addition; Compare analysis from each medication group with the sibutramine positive controls; Embodiment 2 large and small dose groups, embodiment 41 heavy dose of groups, embodiment 9 large and small dose groups compound medicine serum triglycerides and the positive group of sibutramine quite point out these compounds to become the more excellent slimming medicine of result of treatment probably.
Can know by inference, two kinds of compounds (embodiment 8 and embodiment 10 compounds) in addition of embodiment 9 place groups have identical active structure with the compound of embodiment 9, therefore have and the same drug activity of embodiment 9 compounds; And further know by inference, blocking group Boc replaces can not having essence to change to pharmaceutical activity with Cbz or Fmoc.
(2) each medication group is to reaching the sexual organ influence of white adipose tissue weight, sexual organ white adipose cell counting (40 * 10 visual field) on every side on every side around obese rat body weight, Lee coefficient, the kidney
The result is as shown in table 3, and model control group is compared with the blank group, white adipose tissue weight around final body weight, Lee coefficient, the kidney and around the sexual organ, reduce sexual organ around white adipose cytometer number average there were significant differences, show that model is successful; Final body weight, Lee coefficient, kidney that embodiment 41 compound medicines, embodiment 9 compound medicines, sibutramine can obviously reduce obese rat reach sexual organ white adipose tissue weight, the white adipose cell counting on every side of minimizing sexual organ on every side on every side, compare variant or significant difference with model group; Embodiment 41 compound medicines, embodiment 9 compound medicines reach sexual organ white adipose tissue weight, the white adipose cell counting on every side of minimizing sexual organ on every side on every side to final body weight, Lee coefficient, the kidney of obese rat; Compare indifference with sibutramine, all the other each medication groups are compared all variant or significant difference with the sibutramine group; Compare with the blank group, each medication group all has antiobesity action in various degree.As seen from the above analysis; Each is tested medicine and can reduce around the final body weight, Lee coefficient, kidney of obese rat and white adipose tissue weight around the sexual organ, reduce white adipose cell counting around the sexual organ; Antiobesity action is in various degree arranged; Wherein, similar effect is arranged with sibutramine with embodiment 41 compound medicines, embodiment 9 compound medicine drug effects fruit the best.
(3) white adipose cell around each medication group sexual organ, the change of important organ pathological section
Observe pathological section photo (picture is more, does not provide one by one for this reason among the present invention, but provides comprehensive text description), the white adipose cellular form is normal around the normal control group sexual organ, clear border, and in each 40 * 10 times of visual field, the number of adipocyte is normal.The white adipose cell obviously increases around the model group sexual organ, obscure boundary, and soft edge has the tendency of fusion; In each 40 * 10 times of visual field, the number of adipocyte obviously reduces, and diameter increases, and the adipocyte counting has statistically-significant difference with the normal control group.The white adipose cellular form was between model group and normal control group around sexual organ were respectively organized in medication; Wherein, The white adipose cellular form of embodiment 41 compound medicines, embodiment 9 compound medicines is less relatively; Adipocyte counting compares with model control group that there were significant differences, and embodiment 9 compound medicines are compared no difference of science of statistics with sibutramine.
Important organ pathological observation result: the normal control treated animal heart, liver, kidney, ovary, testis are not all seen obvious pathological change; The heavy dose of treated animal heart of medicine of the present invention, liver, kidney, ovary, testis are compared no significant difference with the normal control group, and medicine shown in the demonstration is not seen the vitals infringement except that antiobesity action, point out medicine of the present invention to be expected to alleviate the toxic side effect to body.
Three, conclusion
Each medication group has antiobesity action in various degree, and is wherein best, similar with sibutramine or more excellent with the compound medicine antiobesity action of embodiment 9 place groups and embodiment 41 place groups; Model group, the heavy dose of treated animal heart of The compounds of this invention medicine, liver, kidney, ovary, testis are compared with the normal control group, do not see obvious pathological change.
Each medication group of table 2 is to the influence of obese rat total serum protein, triglyceride level, SUV, blood sugar
Group |
Total serum protein (g/l) |
Serum triglyceride (mmol/l) |
Serum cholesterol (mmol/l) |
Blood sugar (mmol/l) |
The blank group |
76.34±7.99 |
0.95±0.17
▲ |
2.71±0.25
▲ |
4.14±0.50 |
Model group |
72.26±7.83 |
2.77±0.07
■★ |
4.04±0.58
■★ |
4.06±0.55 |
Embodiment 16 chemical drugs are heavy dose of |
76.53±7.15 |
1.99±0.19
▲■ |
2.76±0.20
▲ |
4.29±0.49 |
Embodiment 16 chemical drugs are low dose of |
75.45±7.11 |
2.21±0.36
▲■★ |
2.91±0.17
▲ |
4.06±0.78 |
Embodiment 22 chemical drugs are heavy dose of |
75.37±7.23 |
1.63±0.27
▲■ |
3.26±0.39
▲□ |
4.20±1.35 |
Embodiment 22 chemical drugs are low dose of |
75.58±5.34 |
2.10±0.32
▲■ |
3.43±0.41
△■ |
4.02±0.54 |
Embodiment 12 chemical drugs are heavy dose of |
76.02±5.21 |
1.93±0.62
▲■ |
2.81±0.24
▲ |
4.08±0.80 |
Embodiment 12 chemical drugs are low dose of |
77.66±8.19 |
1.78±0.44
▲■ |
3.23±0.42
△□ |
3.94±1.16 |
Embodiment 26 chemical drugs are heavy dose of |
73.90±5.74 |
1.71±0.12
▲■☆ |
3.09±0.54
▲ |
3.98±0.44 |
Embodiment 26 chemical drugs are low dose of |
72.79±11.6 |
2.73±0.58
▲■★ |
2.68±0.14
▲ |
4.07±0.54 |
Embodiment 14 chemical drugs are heavy dose of |
73.39±7.73 |
2.69±0.43
■★ |
2.64±0.16
▲ |
4.05±0.70 |
Embodiment 14 chemical drugs are low dose of |
73.07±7.99 |
1.93±0.09
▲■☆ |
2.99±0.15
▲■ |
4.21±0.68 |
Embodiment 2 chemical drugs are heavy dose of |
73.45±8.72 |
1.42±0.28
▲■ |
2.86±0.20
▲ |
4.19±0.60 |
Embodiment 2 chemical drugs are low dose of |
75.66±10.3 |
1.44±0.03
▲■ |
3.15±0.38
▲■ |
3.92±0.60 |
Embodiment 40 chemical drugs are heavy dose of |
72.30±7.57 |
1.69±0.17
▲■ |
2.92±0.46
▲ |
4.16±0.98 |
Embodiment 40 chemical drugs are low dose of |
75.09±7.23 |
1.95±0.38
▲■☆ |
2.86±0.30
▲ |
4.23±0.48 |
Embodiment 41 chemical drugs are heavy dose of |
76.06±10.0 |
1.57±0.16
▲■ |
2.60±0.20
▲ |
4.51±0.65 |
Embodiment 41 chemical drugs are low dose of |
75.37±6.93 |
1.91±0.12
▲■☆ |
3.11±0.17
▲■ |
4.18±1.10 |
Embodiment 9 chemical drugs are heavy dose of |
74.44±7.21 |
0.88±0.20
▲ |
2.55±0.20
▲ |
4.16±0.18 |
Embodiment 9 chemical drugs are low dose of |
72.34±7.84 |
1.01±0.06
▲ |
3.01±0.30
▲□ |
4.19±0.47 |
Sibutramine |
74.44±8.39 |
1.24±0.31
▲ |
3.07±0.27
▲ |
4.36±0.69 |
△Compare P<0.05 with model group;
▲Compare P<0.01 with model group;
Compare P<0.05 with the blank group;
■Compare P<0.01 with blank control group;
☆Compare P<0.05 with the sibutramine group;
★Compare P<0.01 with the sibutramine group;
Each medication group of table 3 is to reaching the sexual organ influence of white adipose tissue weight, sexual organ white adipose cell counting (40 * 10 visual field) on every side on every side around obese rat body weight, Lee coefficient, the kidney
Group |
Final body weight (g) |
The Lee coefficient |
Reach sexual organ white adipose tissue weight (g) on every side around the kidney |
Adipocyte counting (40 * 10 visual field) |
The blank group |
189±19
▲★ |
302.70±20.95
▲★ |
2.21±0.23
▲☆ |
117.90±13.71
▲★ |
Model group |
310±71
■★ |
336.63±20.17
■★ |
6.46±2.43
■☆ |
30.60±6.06
■★ |
Embodiment 16 chemical drugs are heavy dose of |
294±67
■☆ |
307.23±19.87
▲★ |
4.73±2.04
■ |
49.70±6.33
▲■★ |
Embodiment 16 chemical drugs are low dose of |
282±71
■ |
309.72±10.15
▲ |
6.22±3.64
■ |
46.60±10.74
▲■☆ |
Embodiment 22 chemical drugs are heavy dose of |
286±58
■☆ |
307.09±11.74
▲★ |
4.44±1.58
△■ |
55.4±7.73
▲■★ |
Embodiment 22 chemical drugs are low dose of |
293±64
■ |
312.05±23.26
△ |
5.32±1.24
■ |
54.60±10.74
▲■ |
Embodiment 12 chemical drugs are heavy dose of |
294±46
■★ |
309.24±16.08
▲ |
5.28±3.15
■ |
48.7±11.66
▲■ |
Embodiment 12 chemical drugs are low dose of |
316±81
■ |
313.57±16.21
△ |
5.62±1.18
■ |
53.60±9.57
▲■ |
Embodiment 26 chemical drugs are heavy dose of |
294±58
■★ |
310.09±25.66
△★ |
4.82±1.51
■ |
51.3±9.71
▲■★ |
Embodiment 26 chemical drugs are low dose of |
311±74
■ |
315.22±13.43
△★ |
5.54±2.37
■ |
52.1±11.97
▲■ |
Embodiment 14 chemical drugs are heavy dose of |
294±68
■☆ |
312.65±14.65
▲★ |
4.43±1.87
■ |
48.10±8.39
▲■★ |
Embodiment 14 chemical drugs are low dose of |
293±54
■ |
317.57±13.45
△☆ |
6.62±1.59
■ |
48.20±8.27
▲■☆ |
Embodiment 2 chemical drugs are heavy dose of |
295±62
■★ |
314.12±14.08
△★ |
4.23±0.81
△■ |
50.02±8.28
▲■★ |
Embodiment 2 chemical drugs are low dose of |
292±61
■ |
310.70±8.23
▲ |
4.88±1.66
■ |
48.00±12.43
▲■ |
Embodiment 2 chemical drug smaller doses |
295±65
■ |
315.31±18.92
△ |
5.30±1.86
■ |
47.10±9.79
▲■ |
Embodiment 40 chemical drugs are heavy dose of |
287±56
■☆ |
318.94±19.49
★ |
4.83±1.64
■ |
450.10±9.09
▲■★ |
Embodiment 40 chemical drugs are low dose of |
269±51
■ |
315.68±17.00
△ |
5.05±1.57
■ |
48.40±10.99
▲■ |
Embodiment 41 chemical drugs are heavy dose of |
251±34
△■ |
294.54±15.23
▲☆ |
4.00±0.66
▲■ |
59.20±8.43
▲■★ |
Embodiment 41 chemical drugs are low dose of |
292±70
■ |
314.52±12.13
▲ |
4.89±2.59
■ |
52.20±6.75
▲■ |
Embodiment 9 chemical drugs are heavy dose of |
242±27
△■ |
283.58±17.77
▲□ |
3.87±2.08
△□ |
68.2±7.93
▲■ |
Embodiment 9 chemical drugs are low dose of |
295±64
■ |
314.44±9.18
▲☆ |
4.80±1.60
■ |
54.80±5.45
▲■ |
The sibutramine group |
227±37
▲■ |
276.31±13.72
▲■ |
3.70±2.19
▲□ |
72.50±10.19
▲■ |
△Compare P<0.05 with model group;
▲Compare P<0.01 with model group;
Compare P<0.05 with the blank group;
■Compare P<0.01 with blank control group;
☆Compare P<0.05 with the sibutramine group;
★Compare P<0.01 with the sibutramine group.
Above description of test the application of The compounds of this invention (comprising racemize, optical isomer and their salt) in pharmacy.Need to prove that in application, in order to reach required biology effect, needed amount depends on multiple factor, the type of for example selected specific compound, desired use, administration and patient's clinical state.Generally speaking, every day dosage in 0.3mg to 100mg scope (usually 3mg to 50mg) every day every kg body weight, for example 3-10mg/kg/ days.Intravenous dosages for example can be in 0.3mg to 1.0mg/kg scope, can be by the mode infusion administration that is fit to, and dosage is the every kg p m of 10ng to 100ng.The infusion solution that is suitable for these purposes for example can contain every milliliter of 0.1ng to 10mg, common 1ng to 10mg.Single dose for example can contain 0.1ng to 10g active compound.Thereby the injection ampoule for example can contain 1mg to 100mg, the single dose preparation of Orally-administrable---for example tablet or capsule---, and for example can contain 1.0 to 1000mg, common 10 to 600mg.Under the situation of pharmacy acceptable salt, above-mentioned quality relates to the quality as the free cpds on salt basis.The compound that is used for prevention of above-mentioned illness or treatment can be according to the compound of formula (I) itself, but they preferably present the form of pharmaceutical composition with acceptable carrier.Certainly carrier must be compatible, that is to say that other compositions of it and said compsn are compatible, and is harmless to patient's health.Carrier can be that solid or liquid or the two all are, preferably is mixed with single dose with compound, and for example tablet wherein can contain 0.05 to 95 weight % active compound.Can also there be other pharmaceutically active substances, comprises other compound according to formula (I).Pharmaceutical composition of the present invention can prepare according to any known method of pharmacy, and these methods comprise in itself mixes acceptable carrier on each composition and the pharmacology and/or auxiliary agent.
Pharmaceutical composition of the present invention is to be suitable for those of oral, rectum, part, per os (for example hypogloeeis) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenously) administration, but optimal administering mode in each single case, depend on the illness that will treat type and seriousness and in each case used type of compounds according to formula (I).Sugar-coated preparation and sugar-coat sustained release preparation are also included within the scope of the invention.Preferred acidproof and resistant to gastric juice preparation.The resistant to gastric juice way layer that is fit to comprises Cellacefate, gathers acetate O-phthalic vinyl acetate, hydroxypropylmethylcellulose phthalate and the anionic polymer of M Cr.
The medicinal compsns that is suitable for oral administration can present independently unit, and for example capsule, cachet, lozenge or tablet contain the compound according to formula (I) of a certain amount in each case; Pulvis or granule; Solution in water-based or non-aqueous liquid or suspension; Perhaps oil-in-water-type or water-in-oil emulsion.As mentioning, said compsn can prepare according to any suitable method of pharmacy, comprises the step that active compound is contacted with carrier (can comprise one or more other components).Generally speaking, compsn is like this preparation, with mixing of the solid carrier uniformity of active compound and liquid and/or fine dispersion, then if necessary, makes the product moulding.Thereby for example, tablet can prepare like this, and the powder or the particle of compacting compound (taking the circumstances into consideration and one or more other components) perhaps make it moulding.Compressed tablet can prepare like this, in suitable machine, suppresses the free-flowing form (for example powder or particle) of compound (taking the circumstances into consideration to be mixed with tackiness agent, releasing agent, inert diluent and/or one or more surfactant/dispersant).Matrix band can prepare like this, in suitable machine, uses the moistening powdered compounds moulding of inert liquid diluent.
Be fit to comprise lozenge with the pharmaceutical composition of per os (hypogloeeis) administration; It contains the compound and the correctives of with good grounds formula (I), is generally sucrose and gum arabic or tragacanth gum, and pastille; It comprises compound in inert base, matrix for example is gelatin and glycerine or sucrose and gum arabic.
The pharmaceutical composition that is suitable for administered parenterally preferentially comprises the sterilized water type preparation according to the compound of formula (I), and they are isoosmotic with the expection person's that receives the medicine blood preferentially.These preparations are intravenous administration preferably, but they also can be used as that injection is subcutaneous, intramuscular or intradermal administration.Under preparation can preferably prepare like this, compound is mixed with water, aseptic the closing in blood etc. of gained solution oozed.Injectable composition of the present invention generally contains 0.1 to 5 weight % active compound.
The pharmaceutical composition that is suitable for rectal administration preferentially presents single dose suppository.They can prepare like this, will mix according to the compound of formula (I) and one or more conventional solid carriers theobroma oil for example, make the gained mixture forming.
The pharmaceutical composition that is suitable for the local skin medication preferably presents ointment, creme, lotion, paste, sprays, aerosol or finish.Operable carrier is the combination of Vaseline, yolk, polyoxyethylene glycol, alcohols and two or more these materials.Generally speaking, the concentration of active compound accounts for 0.1 to 15% of composition weight, and for example 0.5 to 2%.
Transdermal administration also is possible.The pharmaceutical composition that is suitable for transdermal administration can present single patch, and they are fit to closely contact for a long time with patient's epidermis.This type patch is fit to contain the optional aqueous solution that is cushioned of active compound, compound dissolution and/or be dispersed in the tackiness agent or be dispersed in the polymkeric substance.The active compound that is fit to can be released through electrical operation or iontophoresis, Pharmaceutical Research for example, and 2 (6): 318 (1986) is said.
Compound of the present invention is because of remarkable to the beneficial effect of lipid metabolism, and they are particularly suitable for keeping behind Mammals loss of weight and the loss of weight weight that has reduced and are used as anoretics.Compound is remarkable because of their hypotoxicity and less spinoff.Can adopt independent compound or with other losss of weight or subtract the combination of appetite active compound.
The appetite active compound that subtracts that this type is other is for example stated in Roten Liste the 01st chapter loss of weight agent/appetite-inhibiting agent; Can also comprise such active compound, they increase biological energy transformation, thereby cause the minimizing of weight; Perhaps such compound; They influence the general metabolism of said biology, and the calorie intake that is consequently increased can not cause the expansion of said biological fat depot, and normal calorie intake causes the minimizing of fat depot.This compound is suitable for overweight or fat prevention, particularly treatment.This compound is suitable for type ii diabetes, arteriosclerotic prevention in addition, and particularly treatment is suitable for the normalizing and the hypertensive treatment of lipid metabolism.Compound serves as the MCH antagonist, and also being suitable for sensory disturbance and other psychosis indications must treat, for example depression, anxiety neurosis, schizophrenia, and the treatment of the treatment of the obstacle relevant with diel rhythm and drug dependence.
On the other hand; Compound of the present invention can be united the formation compound medicines with one or more other pharmacological active substances, the latter for example can be selected from by antidiabetic, the agent of lipotropism fat, blood pressure reduce active compound, lipid lowering agent and by mellitus cause or with the group that active compound is formed that treats and/or prevents of mellitus complications associated with arterial system.
The antidiabetic that is fit to comprises Regular Insulin, amylin, GLP-1 and GLP-2 verivate, for example is disclosed among the WO98/08871 those and oral hypoglycemic activity compound by Novo NordiskA/S.
Said oral hypoglycemic activity compound preferentially comprises compound, PPAR and rxr agonist that suppressor factor (for example glycogen phosphorylase inhibitor), glucose uptake and glucose excretory modulator, the compound (for example hyperlipidemia active compound and hyperlipemia active compound, for example HMGCoA reductase inhibitor), SUV running/SUV uptake inhibitor, cholic acid cell reabsorption inhibitor or microsomal triglyceride transfer protein (MTP) suppressor factor that change lipid metabolism, the minimizing nutrition agent of the liver enzyme that sulfonylurea, biguanides, meglitinide 、 oxadiazole alkane diketone, U 25560, heteroside enzyme inhibitors, glucagon receptor antagonist, GLP-1 agonist, potassium channel openers (for example being disclosed among WO 97/26265 and the WO 99/03861 those by Novo Nordisk A/S), Regular Insulin to quick dose, insulin receptor kinase acvator, involved in sugar heteroplasia and/or glycogenolysis stimulate absorb and the active compound that acts on β cell ATP dependency potassium channel.
A kind of embodiment of the present invention is that The compounds of this invention and Regular Insulin share with administation of combination.
In another embodiment, The compounds of this invention is composite in order to administation of combination with sulfonylurea, and for example tolbutamide, Glyburide, lattice row do not have urea, Glipizide, gliquidone, RP 22410, glibornuride or GLICLAZIDE B.P. 2000.
In another embodiment, The compounds of this invention and biguanides are composite in order to administation of combination, for example N1,N1-Dimethylbiguanide.
In another embodiment, The compounds of this invention is composite in order to administation of combination with meglitinide, and for example auspicious all kinds of row how.
In another embodiment; The compounds of this invention is composite in order to administation of combination with U 25560; For example troglitazone, ciglitazone, pioglitazone, rosiglitazone (rosiglitazone) or be disclosed in the compound among the WO 97/41097 by Dr.Reddy ' s ResearchFoundation; 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolyl methoxyl group) phenyl] methyl]-2,4-U 25560 particularly.
In another embodiment, The compounds of this invention is composite in order to administation of combination with alpha-glucosidase inhibitor, for example miglitol or acarbose.
In another embodiment, The compounds of this invention is composite in order to administation of combination with the active compound that acts on β cell ATP dependency potassium channel, tolbutamide for example, Glyburide, glimepiride, Glipizide, GLICLAZIDE B.P. 2000 or repaglinide.
In another embodiment; The compounds of this invention is composite in order to administation of combination with lipidemia active compound or hyperlipemia active compound, and for example Colestyramine, colestipol, chlorine Bei Te, luxuriant and rich with fragrance nobert, lucky luxuriant and rich with fragrance Betsy, lovastatin, pravastatin, SV, holder are cut down his spit of fland (atorvastatin), simvastatin (cerivastatin), chlorine and cut down his spit of fland, probucol, ezetimibe or dextrothyroxine.
In another embodiment; A kind of compound is composite with administation of combination with more than one above-mentioned other drug compounds among the present invention, for example sulfonylurea and N1,N1-Dimethylbiguanide, sulfonylurea and acarbose, repaglinide and N1,N1-Dimethylbiguanide, Regular Insulin and sulfonylurea, Regular Insulin and N1,N1-Dimethylbiguanide, Regular Insulin and troglitazone, Regular Insulin and lovastatin etc.
In addition, The compounds of this invention can be composite with administation of combination with one or more lipotropism fat agent or appetite control active compound.This type active compound can be selected from the agonist by CART; The NPY antagonist; The MC4 agonist; Aricine (Oxexin) antagonist; The H3 agonist; The TNF agonist; The CRF agonist; CRF BP antagonist; Urine cortin (urocotin) agonist; β 3 agonists; MSH (black cell stimulation hormone) agonist; The CCK agonist; Serotonin reuptake inhibitors; Mixed type thrombotonin and NRI; The 5HT modulator; The MAO suppressor factor; The plain agonist of Han Wa skin; The galanin antagonist; Tethelin; Growth hormone releasing compounds; The TRH agonist; UCPS 2 or 3 modulators; RMETHU LEPTIN (Leptin) agonist; Dopamine agonist (bromocriptine; Doprexin); Esterase/amylase inhibitor; Cannabined receptor 1 antagonist; Acidylate SP (ASP) modulator; The PPAR modulator; The RXR modulator; The group that hCNTF stand-in or TR-beta-agonists are formed.
In one embodiment of the invention, the agent of lipotropism fat is RMETHU LEPTIN or modification RMETHU LEPTIN.
In another embodiment, the agent of lipotropism fat is Dextroamphetamine or amphetamine.
In another embodiment, the agent of lipotropism fat is Phenfluoramine or Isomeride.
In another embodiment, the agent of lipotropism fat be sibutramine or sibutramine list-with two-demethylation active metabolite.
In another embodiment, the agent of lipotropism fat is an orlistat.
In another embodiment, the agent of lipotropism fat is Mazindol, Diethylpropion or phentermine.
In addition, The compounds of this invention can with one or more antihypertensive active compound administation of combination.The instance of anti-high blood medicine active compound has beta-blocker, alprenolol for example, atenolol USP 23, timolol, pindolol, Proprasylyte and Mei Tuogeer; ACE (angiotensin-converting enzyme) suppressor factor; For example benazepril, captopril, enalapril, fosinopril, Lenno Puli and ramipril, calcium channel blocker; For example nifedipine, felodipine, nicardipine, Isrodipine, nimodipine, Odizem and verapamil; And alpha blocker, UK-33274 for example, urapidil, Prazosin and terazosin.In addition, can be with reference to Remington:The Science andPractice of Pharmacy, 19th edition, Gennaro, editor, Mack Publishing Co., Easton, PA, administation of combination is carried out in 1995 introduction.
Self-evident, steric isomer compound of the present invention and one or more above-claimed cpds with choose any one kind of them or every kind of suitable combination of multiple other pharmacological active substance also all should be regarded as being covered by protection domain of the present invention.